Philip Rowe

740 total citations · 1 hit paper
7 papers, 389 citations indexed

About

Philip Rowe is a scholar working on Oncology, Reproductive Medicine and Molecular Biology. According to data from OpenAlex, Philip Rowe has authored 7 papers receiving a total of 389 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 4 papers in Reproductive Medicine and 3 papers in Molecular Biology. Recurrent topics in Philip Rowe's work include PARP inhibition in cancer therapy (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and BRCA gene mutations in cancer (3 papers). Philip Rowe is often cited by papers focused on PARP inhibition in cancer therapy (6 papers), Ovarian cancer diagnosis and treatment (4 papers) and BRCA gene mutations in cancer (3 papers). Philip Rowe collaborates with scholars based in United Kingdom, United States and Australia. Philip Rowe's co-authors include Jonathan A. Ledermann, Tamar Safra, Clare L. Scott, Anitra Fielding, Ursula A. Matulonis, Charlie Gourley, Michael Friedländer, Darren Hodgson, Ronnie Shapira‐Frommer and Elizabeth Lowe and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Clinical Cancer Research.

In The Last Decade

Philip Rowe

7 papers receiving 381 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial

2016 309 citations Jonathan A. Ledermann, Philipp Harter et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Philip Rowe United Kingdom	6	328	201	152	112	44	7	389
Valerie Bowering Canada	10	310 0.9×	176 0.9×	168 1.1×	59 0.5×	37 0.8×	28	378
Dale W. Garsed Australia	7	257 0.8×	127 0.6×	195 1.3×	67 0.6×	68 1.5×	12	397
Alison Freimund Australia	8	276 0.8×	126 0.6×	139 0.9×	29 0.3×	50 1.1×	11	375
S. M. Domchek United States	8	317 1.0×	80 0.4×	143 0.9×	100 0.9×	98 2.2×	21	400
Dana‐Adriana Botesteanu United States	6	304 0.9×	117 0.6×	167 1.1×	30 0.3×	47 1.1×	9	411
K.M. Bell-McGuinn United States	5	152 0.5×	113 0.6×	81 0.5×	76 0.7×	36 0.8×	10	219
C. Whalen United States	5	163 0.5×	149 0.7×	106 0.7×	28 0.3×	16 0.4×	13	233
Tabari M. Baker United States	6	265 0.8×	40 0.2×	234 1.5×	63 0.6×	98 2.2×	12	406
Iulia Cirlan Canada	2	90 0.3×	52 0.3×	138 0.9×	26 0.2×	31 0.7×	3	246
E. Hitt Nichols United States	3	231 0.7×	91 0.5×	83 0.5×	13 0.1×	19 0.4×	5	267

Countries citing papers authored by Philip Rowe

Since Specialization

Citations

This map shows the geographic impact of Philip Rowe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip Rowe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip Rowe more than expected).

Fields of papers citing papers by Philip Rowe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip Rowe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip Rowe. The network helps show where Philip Rowe may publish in the future.

Co-authorship network of co-authors of Philip Rowe

This figure shows the co-authorship network connecting the top 25 collaborators of Philip Rowe. A scholar is included among the top collaborators of Philip Rowe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip Rowe. Philip Rowe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

7 of 7 papers shown

1.

Willis, Sophie E., C Winkler, Martine P. Roudier, et al.. (2021). Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response. British Journal of Cancer. 125(12). 1666–1676. 31 indexed citations

2.

Fujiwara, Keiichi, Hiroyuki Fujiwara, Hiroyuki Yoshida, et al.. (2021). Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. Journal of Gynecologic Oncology. 32(5). e82–e82. 7 indexed citations

3.

Fielding, Anitra, Jordi Bertrán-Alamillo, Brian Dougherty, et al.. (2017). Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. Annals of Oncology. 28. v626–v626. 3 indexed citations

4.

Gourley, Charlie, Michael Friedländer, Ursula A. Matulonis, et al.. (2017). Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).. Journal of Clinical Oncology. 35(15_suppl). 5533–5533. 18 indexed citations

5.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. The Lancet Oncology. 17(11). 1579–1589. 309 indexed citations breakdown →

6.

Ledermann, Jonathan A., Philipp Harter, Charlie Gourley, et al.. (2016). Overall survival (OS) in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC) receiving olaparib maintenance monotherapy: An interim analysis.. Journal of Clinical Oncology. 34(15_suppl). 5501–5501. 11 indexed citations

7.

Nilsson, Monique B., Uma Giri, Jayanthi Gudikote, et al.. (2015). KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib. Clinical Cancer Research. 22(8). 1940–1950. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact